Physician profile
Prina Patel
NPI 1205568797
$1,923.67
in general payments reported to CMS, 2019-2025
12 companies · $652 in 2025
The $652 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.09 · 2023: $670 · 2024: $576 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $459.49 | 2022-2025 | Total30, Rocklatan, Precision7 |
| Tarsus Pharmaceuticals, INC. | $344.13 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $291.07 | 2023-2025 | Xiidra, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $283.60 | 2023 | Acuvue |
| Sight Sciences, INC. | $147.91 | 2023 | Tearcare System |
| Apellis Pharmaceuticals, INC. | $121.84 | 2023 | Syfovre |
| Sun Pharmaceutical Industries INC. | $108.84 | 2024-2025 | |
| Coopervision INC. | $44.69 | 2023-2025 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $43.41 | 2024 | Ryzumvi, Tyrvaya |
| Kedrion Biopharma, INC. | $34.93 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Abbvie INC. | $22.11 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.65 | 2025 | Eylea Hd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.